Mirtazapine Tapering Protocol
Gradually reduce mirtazapine by the smallest dose increment possible over several weeks to months, rather than stopping abruptly, to minimize withdrawal symptoms including dizziness, sensory disturbances, agitation, anxiety, and nausea.
FDA-Approved Tapering Guidance
The FDA drug label explicitly states: "Gradually reduce the dosage of mirtazapine tablets rather than stopping abruptly whenever possible" 1. Adverse reactions upon discontinuation include dizziness, abnormal dreams, sensory disturbances (including paresthesia and electric shock sensations), agitation, anxiety, fatigue, confusion, headache, tremor, nausea, vomiting, and sweating 1.
Recommended Tapering Schedule
Based on guideline evidence for psychotropic medication discontinuation, the following approach should be used:
Standard Risk Patients
- Reduce dose by the smallest increment possible (typically 25% reductions)
- Interval between reductions: at least several days to 1-2 weeks 2, 3
- Total tapering duration: several weeks to months 2
Practical Implementation for Mirtazapine
Given that mirtazapine comes in 15 mg, 30 mg, and 45 mg tablets:
For patients on 30 mg:
- Week 0-2: 22.5 mg daily (can split 45 mg tablet)
- Week 2-4: 15 mg daily
- Week 4-6: 7.5 mg daily (split 15 mg tablet)
- Week 6-8: 7.5 mg every other night
- Week 8+: Discontinue
For patients on 45 mg:
- Week 0-2: 30 mg daily
- Week 2-4: 22.5 mg daily
- Week 4-6: 15 mg daily
- Week 6-8: 7.5 mg daily
- Week 8-10: 7.5 mg every other night
- Week 10+: Discontinue
Critical Warnings About Alternate-Day Dosing
Do not use alternate-day dosing as a primary tapering strategy at therapeutic doses. Recent evidence demonstrates that prolonging the inter-dose interval at standard doses causes pronounced increases in receptor occupancy variation, which likely increases withdrawal symptom risk 4. Alternate-day dosing should only be used at very low doses (e.g., 7.5 mg) near the end of the taper 2.
High-Risk Patients Requiring Slower Taper
Patients at higher risk for withdrawal symptoms may require hyperbolic (non-linear) tapering over months to years, with smaller percentage reductions as the dose decreases 5, 6:
Risk factors for severe withdrawal:
- Duration of treatment >6 months
- Previous difficulty stopping antidepressants
- History of withdrawal symptoms
- Higher doses (>30 mg)
For these patients, consider:
- 10-20% dose reductions every 2-4 weeks
- Tapering down to very low doses (1-2 mg) before complete cessation
- May require liquid formulations or compounded preparations for precise small doses 6
Monitoring During Taper
Assess every 2-4 weeks during tapering 5:
- Withdrawal symptoms (dizziness, sensory disturbances, anxiety, insomnia)
- Depressive symptom recurrence
- Sleep disturbances
- Gastrointestinal symptoms
If withdrawal symptoms emerge:
- Return to previous dose and stabilize
- Resume tapering at slower rate (smaller decrements, longer intervals)
- Consider extending total taper duration
Distinguishing Withdrawal from Relapse
Withdrawal symptoms typically:
- Occur within 2-3 days of dose reduction
- Peak at 1-3 days
- Include physical symptoms (dizziness, paresthesias, electric shock sensations)
- Improve with dose restoration 2
Relapse symptoms typically:
- Emerge gradually over 2+ weeks
- Reflect original depressive symptoms
- Do not include prominent physical symptoms
- Do not improve rapidly with dose restoration
Case Evidence
A documented case report demonstrates the risk of abrupt discontinuation: a patient on 30 mg for 10 weeks who abruptly stopped developed severe, recurring panic attacks every 1-2 hours for 5 days, which only resolved after restarting mirtazapine 7. This underscores that even medium-duration treatment (10 weeks) requires gradual tapering.
Adjunctive Support
While tapering, consider:
- Cognitive-behavioral therapy (increases successful discontinuation rates) 2
- Management of specific withdrawal symptoms (e.g., trazodone for insomnia if needed short-term) 8
- Patient education about expected withdrawal timeline
- Close clinical follow-up with option to pause or reverse taper
Common Pitfalls to Avoid
- Never stop mirtazapine abruptly - even after short-term use 1, 7
- Do not use alternate-day dosing at therapeutic doses - causes receptor occupancy fluctuations 4
- Do not taper too quickly - minimum several days between reductions 2
- Do not mistake withdrawal for relapse - withdrawal occurs rapidly (days), relapse gradually (weeks)
- Do not use fixed tapering schedules for high-risk patients - individualize based on response 5